Click image to enlarge

NEWS: February 13, 2008 Johnson & Johnson Duragesic Pain Patch Flaw Recall:
A recall has been issued by Johnson & Johnson and Novartis AG's Sandoz on 25-microgram-per-hour patches with expiration dates on or before December 2009.

It was found that a manufacturing problem led to some of the patches having a cut in the internal reservoir lining. This cut may cause a leaking problem of the patch.
The danger is if anyone touches a defective pain patch they may be delivered a dose of the prescription painkiller fentanyl which may lead to breathing problems or even an accidental overdose.

Back in December the FDA issued a safety warning on the Duragesic patch, citing improper use may cause breathing difficulties and death.
The FDA continues to work with J& J on this voluntary recall and is investigating this latest issue.

If you have been injured or have lost a loved one due to exposure to a fentanyl patch, you need to seek legal guidance from an experienced attorney as soon as possible. You have the right to seek justice against the careless pharmaceutical companies who failed to warn their consumers about these dangerous and deadly product defects in a more timely manner. Don’t become another victim of corporate irresponsibility.

On April 5th, 2004, Janssen Pharmaceutical Products, L.P. announced that it was recalling over two million Duragesic® pain control patches due to a potentially deadly defect. The recall was for all 75 mcg. patches with the following lot numbers: 0327192, 0327193, 0327294, 0327295 and 0330362. Click here to see the photos showing the location of the control number and dosage strength.

The defect could result in a leak and lead to a dangerous overdose of the narcotic fentanyl. Fentanyl, the drug contained in the patch, is a potent opioid and a DEA Schedule II controlled substance that is up to 100 times stronger than morphine. In addition to the lots involved in the recall, leaks and similar problems have also been reported for other strength patches and other lot numbers.

Duragesic is no longer the only fentanyl pain patch being marketed. On January 28, 2005, the U.S. Food and Drug Administration (FDA) granted final approval for Mylan Laboratories, Inc. to market a generic fentanyl transdermal system. The manufacturer of Duragesic® has also begun to market an authorized generic version of the fentanyl patch through an agreement with Sandoz. Other companies have applications pending at the FDA to market similar fentanyl patches, therefore, other generic versions may soon be available. Problems associated with these newer generic patches have also been reported.

Contact us today for a free confidential consultation

The following language is required pursuant to Rule 7.2, Alabama Rules of Professional Conduct. No representation is made that the quality of legal services to be performed is greater than the quality of legal services performed by other lawyers. This web site is designed for general information only. The information presented at this site should not be construed to be formal legal advice nor the formation of a lawyer/client relationship.

Free Case Review

Duragesic News:

July 15, 2005
U.S. Warns Fentanyl Patients About Drug
Read Article...

Feb 23, 2004
FDA recalls specific batch of Duragesic (fentanyl) transdermal patches
Read Article...